Venture capital-backed biopharmaceutical company Eleven Biotherapeutics has raised $50m via an IPO on the Nasdaq exchange.
The company offered 5m shares prices at $10 per share and granted the underwriters a 30-day option to acquire an additional 750,000 shares to cover over-allotments.
Citigroup, Cowen and Company and Leerink Partners acted as joint bookrunners for the IPO.
The company is backed by Third Rock Ventures, Flagship Ventures and Jafco.
Eleven Biotherapeutics is a clinical stage company with a protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye.
Copyright © 2014 AltAssets